Most Read Articles
Stephen Padilla, 12 Dec 2019
Transitioning from bortezomib- to ixazomib-based induction is feasible, tolerable and effective in the treatment of community patients with newly diagnosed multiple myeloma (NDMM), according to a study presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
Jackey Suen, 24 Feb 2017

Research on the role of circulating tumour DNA (ctDNA) in metastatic castration-resistant prostate cancer (mCRPC) gains momentum, as a new study finds ctDNA assessment promising in the monitoring and prognosis of mCRPC and in identifying new therapeutic targets for the disease.

13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.
Dr Margaret Shi, 13 Feb 2020

Immunotherapy-chemotherapy combinations, immunotherapy doublets, and combinations of immunotherapy with novel targeted agents are emerging as strategies for management of metastatic urothelial carcinoma (mUC) in view of the limitations with chemotherapy and single-agent immunotherapy, said an expert at the Uro-Oncology Asia 2020 conference. 

BMI at younger vs older age strongly predicts pancreatic cancer

10 Nov 2019

A higher body mass index (BMI) appears to translate to an increased risk of developing pancreatic cancer in men and women aged <50 years but not in those who are older, a study has found.

The study used data from the Cancer Prevention Study-II in 1982 and included 963,317 adults (55.94 percent female) aged 30–89 years at baseline. The average age at BMI assessment was 56 years.

During follow-up through 2014, 8,354 participants died of pancreatic cancer. Proportional hazards regression showed that the risk of pancreatic cancer declined steadily with age at BMI assessment. Hazard ratios (HRs) per 5 BMI-units ranged from 1.25 (95 percent confidence interval [CI], 1.18–1.33) in those aged 30–49 years to 1.13 (95 percent CI, 1.02–1.26) in those aged 70–89 years (p-trend=0.005).

Researchers noted that based on an HR estimate of 1.25 per 5 BMI-units at age 45 years, 28 percent of pancreatic cancer deaths in the US among individuals born from 1970–1974 will be attributable to BMI >25 kg/m2. This number is nearly twice the estimated 15 percent pancreatic cancer deaths among men and women born in the 1930s, a birth cohort with much lower BMI in middle age.

The present data suggest that BMI measured only at older ages is unlikely to fully capture the impact of high BMI earlier in life on the risk of pancreatic cancer, the researchers said. They emphasized the importance of preventing weight gain before middle age, at both individual and community-level, for reducing rates of this highly fatal cancer in the 2030s and beyond.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 12 Dec 2019
Transitioning from bortezomib- to ixazomib-based induction is feasible, tolerable and effective in the treatment of community patients with newly diagnosed multiple myeloma (NDMM), according to a study presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
Jackey Suen, 24 Feb 2017

Research on the role of circulating tumour DNA (ctDNA) in metastatic castration-resistant prostate cancer (mCRPC) gains momentum, as a new study finds ctDNA assessment promising in the monitoring and prognosis of mCRPC and in identifying new therapeutic targets for the disease.

13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.
Dr Margaret Shi, 13 Feb 2020

Immunotherapy-chemotherapy combinations, immunotherapy doublets, and combinations of immunotherapy with novel targeted agents are emerging as strategies for management of metastatic urothelial carcinoma (mUC) in view of the limitations with chemotherapy and single-agent immunotherapy, said an expert at the Uro-Oncology Asia 2020 conference.